Summary
SARS-CoV-2 variant Omicron (B.1.1.529) was classified as a variant of concern (VOC) on November 26, 2021. (1, 2) The infectivity, severity, and immune evasion properties of Omicron relative to the Delta variant would determine 1) the probability of dominant future transmission, and 2) the impact on disease burden. (3, 4) Here we apply individual-based transmission model OpenCOVID to identify thresholds for Omicron’s or any VOC’s potential future dominance, impact on health, and risk to health systems; and identify for which combinations of viral properties, current interventions would be sufficient to control transmission. We show that, with first-generation SARS-CoV-2 vaccines (5) and limited physical distancing in place, the threshold for Omicron’s future dominance was primarily be driven by its degree of infectivity. However, we identified that a VOC’s potential dominance will not necessarily lead to increased public health burden. Expanded vaccination, that includes a third-dose for adults and child vaccination strategies, was projected to have the biggest public health benefit for a highly infective, highly severe VOC with low immune evasion capacity. However, a highly immune evading variant that becomes dominant would likely require alternative measures for control, such as strengthened physical distancing measures, novel treatments, and second-generation vaccines. These findings provide quantitative guidance to decision-makers at a critical time while Omicron’s properties are being assessed and preparedness for new VOC’s is eminent. (6) We emphasize the importance of both genomic and population epidemiological surveillance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for the study was provided by the Botnar Research Centre for Child Health (to MAP) and the Swiss National Science Foundation Professorship of MAP (PP00P3_170702)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We updated several figures and text related.
Data Availability
Data sharing is not applicable to this article as no datasets were generated or analysed during the study. Data informing model parameters are described in Shattock et al. All model code and Figure code are open access and publicly available at (https://github.com/SwissTPH/OpenCOVID). For this paper model code and Figure code are version 2.0 of OpenCovid.
